On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
NEW YORK, May 11, 2026 /PRNewswire/ -- Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on developing treatments for neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results